John Libbey Eurotext

Sang Thrombose Vaisseaux

Place du fondaparinux dans la prise en charge des syndromes coronariens aigus Volume 19, numéro 7, Septembre 2007

1 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes. Comparison of fondaparinux and enoxaparin in aute coronary syndromes. N Engl J Med 2006 ; 354 : 1464-76.

2 Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA 2006 ; 295 : 1519-30.

3 Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation : a meta-analysis. Lancet 2000 ; 355 : 1936-42.

4 Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction : a meta-analysis of the randomized trials. Circulation 2005 ; 112 : 3855-67.

5 Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006 ; 354 : 1477-88.

6 Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006 ; 355 : 1006-17.

7 Petitou M, Herault JP, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999 ; 398 : 417-22.

8 Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001 ; 345 : 1305-10.

9 Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001 ; 345 : 1298-304.

10 Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999 ; 81 : 214-20.

11 Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001 ; 22 : 1716-24.

12 Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes : the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004 ; 43 : 2183-90.

13 Schiele F, Legalery P, Didier K, et al. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. Am Heart J 2006 ; 151 : 661-7.

14 Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes : the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003 ; 24 : 1815-23.

15 Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005 ; 26 : 804-47.

16 Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006 ; 114 : 774-82.

17 Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005 ; 96 : 1200-6.

18 Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes : results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005 ; 46 : 1490-5.

19 Rao SV, O’Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006 ; 47 : 809-16.

20 Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors : results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006 ; 114 : 1380-7.

21 Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005 ; 294 : 3108-16.

22 Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001 ; 344 : 619-25.